Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications CE Mark received for Optune Pax® ...
Barchart Research What to Expect from NVCR Earnings NVCR Generated July 22, 2026 Current Price $15.57 EPS Estimate $$-0.30 Consensus Rating Moderate Buy Average Move 10.36% NovoCure's Profitability Path...
NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised...
NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised...
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and...
The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with...
NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or “the Company”) (NASDAQ:...
Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday...